Blog

  • Monolog 18 – Interleakin’

    Monolog 18 – Interleakin’

    In this monolog, Akshat ponders about the spatiotemporal underpinnings of cytokine concentrations in tissue niches…and how it all appears to function like a gossip network.

    Check out our memes on Facebook (@antibuddies), Twitter (@antibuddiesP), and Instagram (@AntibuddiesPodcast).

    YouTube channel: https://www.youtube.com/channel/UCxyrHotyyY3sSwcp1zigeCw

    Send us your queries/questions/suggestions at antibuddies1@gmail.com.

    Website: Antibuddies – Science Communication & Immunology (Antibuddies.org)

    Sources:

    Collectivist Model: https://www.nature.com/articles/s43018-020-0038-2

    Rapid Switching Model: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562415/

    Competitive Model: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126146/

    Leaky Synapses: https://www.nature.com/articles/nri3242

  • Monolog 17 – CAR-T and TCR-T cells face off

    In this episode, Akshat outlines the salient features of CAR or TCR-engineered T cells, and deigns to ponder: is one modality just objectively better than the other?

    Check out our memes on Facebook (@antibuddies), Twitter (@antibuddiesP), and Instagram (@AntibuddiesPodcast).

    YouTube channel: https://www.youtube.com/channel/UCxyrHotyyY3sSwcp1zigeCw

    Send us your queries/questions/suggestions at antibuddies1@gmail.com.

    Website: Antibuddies – Science Communication & Immunology (Antibuddies.org)

  • Monolog 16 – 217 COVID boosters and Couting

    Monolog 16 – 217 COVID boosters and Couting

    In this Monolog, Casey discusses the unique case of a hyper-vaccinated individual in Germany with more than 200 COVID-19 vaccines and how his immunological profile looks like.
    Check out our memes on Facebook (@antibuddies), Twitter (@antibuddiesP), and Instagram (@AntibuddiesPodcast).
    YouTube channel: https://www.youtube.com/channel/UCxyrHotyyY3sSwcp1zigeCw
    Send us your queries/questions/suggestions at antibuddies1@gmail.com.
    Website: Antibuddies – Science Communication & Immunology (Antibuddies.org)


    Sources:
    https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00134-8/fulltext

  • The Inhalers Within: CAR-Ts for Eosinophil-driven Asthmatic Disease

    The Inhalers Within: CAR-Ts for Eosinophil-driven Asthmatic Disease

    Want your article featured in Antibuddies blog? Contact editor-in-chief Kevin Merchant at antibuddies1@gmail.com.

  • What do cells do at antibuddies?

    What do cells do at antibuddies?

    Want your article featured in Antibuddies blog? Contact editor-in-chief Kevin Merchant at antibuddies1@gmail.com.

  • Break DNA to make memories!

    Break DNA to make memories!

    With the constant inflow of information, one can assume that neurons, the fundamental units of information storage, are constantly writing and editing their personal diaries of memories. Scientifically speaking, every time an extra piece of data is taken in by the host, the neurons adapt, structurally as well on a molecular level, and sort themselves more and more into specific clusters, with each cluster roughly representing a particular sort of memory. This again is a far cry given how stochastic and turbulent this process is and that a particular memory cannot be isolated in this dense yet insanely organized information jungle. Recently new progress has been made by Jovasevic and colleagues in discerning how the immune system might have a crucial role in helping to create stable, context-based memories.

    To this end they decided to go along with the easiest to induce fear sourced memory. They put mice in a container with cameras watching them and gave them tiny electric zaps preceded by an alarm/sound which acts as the context. If the mouse successfully registers a fear memory, then every time the alarm blares before the zap, the mouse literally freezes in fear(I would probably hightail it but hey every mammal for itself). Therefore, the duration of this frozen response is proportional to the quality of the memory that induces it.

    The brain’s memory manager, the hippocampus, is known to be occupied by 50,000 to about 100,000 neurons. These neurons are in turn split up into four types, CA1, CA2, CA3 and CA4, with each population coordinating and uniquely contributing to making memories.   

    To see how the mouse’s neurons were able to learn from experience and orchestrate such a response, they decided to study the CA1-type neurons. These neurons are vested with the function of integrating information from the other neurons in the hippocampus, helping develop spatial memory, contemplate patterns, and of course, create context-based memories, making them prime targets of this study.

    When it came down to studying the molecular events in these neurons during memory creation, the group saw something really weird happening . Usually, memory-making involves switching on a bunch of genes and creating some changes in gene expression and voila! A memory gets created. But here,  the CA1 neurons were using a more violent approach to forge memories.

    Using fluorescence-inducing genes and the right promoters, the group demonstrated that the neurons were undergoing DNA damage in their non-coding regions during the memory-making process. Following DNA damage, the nuclear membrane was ruptured, leading to DNA leakage into the perinuclear space, which was observed a few days after the experiment. These DNA fragments were then subsequently detected by the immune sensor, Toll-like receptors 9 or TLR9, in the endoplasmic reticulum of these neurons. TLR9s are pretty common in the world of immunology, serving as useful receptors for innate immune cells. Beyond that, they are also available in other cells like epithelial – where they play a role in their proliferation – and cancer. As immune sensors, they are normally on the lookout for exogenous DNA, an indication of a probable viral invasion, or mitochondrial DNA which indicates cellular stress and perhaps even apoptosis.

     So, in these neurons when the leaked-out DNA is recognized by TLR9, it triggers an inflammatory state, while also very conveniently initiating DNA damage repair parallelly. Once the damages are fixed successfully, the researchers observed that a stable memory was created in the mice.

    Given the role of TLR9 in this whole memory-making business, it becomes obvious that inhibiting or abrogating it can lead to some serious consequences. Imagine a situation where the neuron keeps breaking its DNA and nobody’s around to fix the damage and restore homeostasis. Not only does the neuron fail at making the memory but it also ends up slowly creeping towards genomic instability and eventual death. It’s like breaking down a house for renovation and fixing but then forgetting the part where you actually fix it. This could lead to neurodegeneration, accelerated senescence, psychiatric disorders, and loss of cognition. Hence the authors warrant a caution against the use of TLR9 antagonist therapies when dealing with neuroimmune conditions such as multiple sclerosis, where TLR9s play an active role in its pathogenesis and inhibiting its activity can be therapeutic. But given this research, the patients being treated using the antagonists might as well be trading one problem for another.

    Personally I find it intriguing how something so risky as this could have developed  into a well regulated and controlled mechanism of memory generation over the course of evolution and what could have possibly evoked its need.  Since DNA damage is usually associated with bad stuff in our bodies, this discovery gives a nice shift to our perspective, adding another entry to the list of destructive things in our body that can have constructive outcomes, here, a strong, stable, memory.

    Source:
    Jovasevic V, Wood EM, Cicvaric A, Zhang H, Petrovic Z, Carboncino A, Parker KK, Bassett TE, Moltesen M, Yamawaki N, Login H, Kalucka J, Sananbenesi F, Zhang X, Fischer A, Radulovic J. Formation of memory assemblies through the DNA-sensing TLR9 pathway. Nature. 2024 Apr;628(8006):145-153. doi: 10.1038/s41586-024-07220-7. Epub 2024 Mar 27. PMID: 38538785; PMCID: PMC10990941.


    Want your article featured in Antibuddies blog? Contact editor-in-chief Kevin Merchant at antibuddies1@gmail.com.

  • Disbelievers beware! Another victory for mRNA vaccines.

    Disbelievers beware! Another victory for mRNA vaccines.

    In 2024, COVID-19 entered its senior year at the University of pandemics, with the world almost back to the norm, all thanks to the mRNA vaccines. The common misconception associated with mRNA vaccines, something I was a victim of myself, is that the immunity offered by these vaccines isn’t long-term and wanes off quickly. While the government in every country was pushing for booster doses to keep the immunity going, which is the best thing you can do in the heat of a raging pandemic, it became even more conducive for the public to believe that maybe the protection offered by the vaccine is, a ‘here today, gone tomorrow’ affair.

    After all this time finally, Srivastava and his group conducted a longitudinal cohort study consisting of 501 individuals to settle the debate once and for all. This study had a very statistically solid foundation, since these 501 individuals, both immune and naïve to COVID-19 were tracked over a period of 3 years, with over 8000 visits, making it a marvelous feat of scientific persistence. In fact, this study even has a special name for itself, PARIS (Protection Associated with Rapid Immunity to SARS-CoV-2).  Analyzing the data that was collected, the researchers used a biphasic mathematical model to predict and study antibody kinetics in two types of individuals; the hybrids, people who’d already experienced an infection before getting vaccinated, and the naïve, whose first contact was the vaccination itself. They found that after getting vaccinated, the antibody levels initially spike in the body, hang around for quite some time, and eventually start decaying (the first phase).

     But hold on, that’s not the end of it.

    Soon enough the antibody levels start going back up again until they stabilize at a particular amount (the second phase), granting the well-promised long-term immunity. This timeline of events fulfills the prophecy of B cell lore, with the first part being played by rapidly proliferating plasmablasts, their disappearance, and then the continuation of the responsibilities by memory B cells in the bone marrow. People already exposed to the virus prior to vaccination reach higher levels of serum antibodies compared to naive individuals, but a booster dose levels the high grounds with serum antibody levels equalizing post-booster for both parties.

    Interesting patterns were seen through the series of vaccinations and booster doses in the cohort. In the case of naïve individuals, a breakthrough infection seemed to boost immunity as did a vaccine in the case of hybrid individuals, where a second infection didn’t do much. The authors speculate that this could be due to the pre-existing immunity in the latter, which needs more than just a puny secondary infection to induce any significant increase in the defense stats. Additionally, they corroborated the results of prior research that Moderna vaccines are indeed better than Pfizer at inducing long-term immunity in initially naive individuals.

    People with hybrid immunity tend to have relatively severe side effects from the vaccinations, which progressively decrease with additional vaccinations. These “side effects” are usually short-lived and are indications of the immune system warming up, hence should not be blown out of proportion. This is something the group promises to study in the future, including how this varying yet anticipated reactogenicity (i.e prolonged bouts of fever, myalgia, allergic reactions at the site of administration) might influence the development of immunity in an individual.

    Hence, through this study, we now know that mRNA vaccines can be effective against COVID-19 infections in the long run by maintaining humoral immunity, something that was hard to gauge using short-term studies. As more time passes by, we hope scientists will be able to study and shed light on other effects that COVID might have on us (including illnesses like long COVID). We are just getting started with 2024 and science has already bagged its first win!


    Want your article featured in Antibuddies blog? Contact editor-in-chief Kevin Merchant at antibuddies1@gmail.com.

  • One more breath during the storm: Treating lung cancer using inhaled IL-12 mRNA 

    One more breath during the storm: Treating lung cancer using inhaled IL-12 mRNA 

    Thousands of methods are being tested to fight the cell cycle abnormality we call cancer. Indeed, they all need to cross the red toxicity line to be safely used. Among those cancer types, lung cancer has the lowest survival rate simply because the symptoms do not appear in its early stages. However, interleukin-12 (IL-12) showed the potential to suppress pulmonary tumours in different studies, but its off-target toxicity has already limited its usage. 

    Therefore, a group of scientists from Columbia University tried to take advantage of the IL-12’s power by re-arming it as an inhalable extracellular IL-12 vector! GENIUS!

    Their experimental setup was to use this inhalable extracellular vector as a direct delivery for IL-12 mRNA into the mouse lungs, which, in theory, would limit the off-target toxicity and localize the IL-12 translation. To this end, the group prepared two vectors: IL-12 mRNA exo and IL-12 mRNA lipo. The difference is in the type of vectors; they used human embryonic kidney cell-derived exosome as a vehicle for IL-12 Exo, while liposome was used for IL-12 mRNA lipo. 

    Their study shows that 24h post-inhalation, IL-12 exo was presented and absorbed more in the tumour microenvironment (TME) than the lipo. And guess what? Even the immune cells could absorb the vectors! The IL-12 exo also showed fantastic results in suppressing the tumour in the mice’s lungs. Besides that, the exosomes induced IFNγ expression into the TME, attracting more active immune cells, which also meant replenishing immune cells for the battle against the tumour. 

    After 30 days of treating the mice with IL-12 exo and IL-12 lipo, the group observed that CD8+ T cells and natural killer cells were still secreting IFNγ into the TME. Plus, the vectors were able to induce memory cell development. I mean, what more do we want more than lifelong protection?

    Now to the safety, aka the cherry on top. The group evaluated the toxicity and observed the mice closely during the six-week experiment. They found no significant weight loss in the body nor the tissues. Also, they went further and stained the primary organs to look for any lesions outside the lungs, and none were observed. 

    The scientists mentioned that the inhalation method could not suit those who have respiratory complications; moreover, it has a long shot until breaking a foot in the clinical trial, yet can you imagine how wild it can be if cancer can be treated with something as simple as an inhaler?


    Want your article featured in Antibuddies blog? Contact editor-in-chief Kevin Merchant at antibuddies1@gmail.com.

  • Family Feud: The Conundrum of Effector Cell Fratricide in Adoptive T cell Therapies

    Family Feud: The Conundrum of Effector Cell Fratricide in Adoptive T cell Therapies

    Before we really get into this, I need you to know that my relationship with my brother is just fine, thankyouverymuch. We get along great, in fact.

    Anyway, fratricide.

    As someone whose work centers around adoptive T cell therapies for cancer, T cell fratricide represents a nightmare scenario. The last thing you want is for your immunotherapeutic T cells to start killing each other, while the tumour chills out in the foreground.

    In 2011, Mathias Leisegang, Sussane Wilde and colleagues at The Max Delbruck Centre for Molecular Medicine in Berlin showed that when T cells engineered to target survivin—an antigen expressed by tumour cells—were infused into a patient of a matching HLA type, those T cells died and the tumour thrived. Now, proliferating T cells make a lot of survivin themselves, and thus they became targets of their survivin-specific brother T cells. Understand that there is seemingly no difference between survivin expressed by T cells (on the given HLA) and tumor-borne survivin, and this example defines the very crux of target-dependent T cell fratricide.

    Happily, this problem isn’t insurmountable. One strategy is outlined by Xiang et al in their paper where they pondered how to make non-fratricidal CAR Ts when attempting to take out CD2+ malignancies. This is a big ask of a CAR-T therapy. T cells are high expressors of CD2 given that it serves as a co-stimulatory molecule involved in all things from thymocyte development to immunological synapse formation. Ergo, a CAR directed to attack anything that expresses CD2 is very likely to cause carnage in the blood itself!

    So, Xiang et al CRISPR’d out CD2 from their CAR and, predictably, found that these cells exerted poor tumor control: the IFNγ and Granzyme they had the potential to make (as determined by single-cell secretome analysis), wouldn’t fill a molecular shot glass. This is…not great. However, these investigators decided to arm their CD2 knockout CARs with a long-acting recombinant IL-7, and they found that the functional impairment caused by CD2’s absence was reversed. The CAR-Ts were in high cotton: good cytokine and cytolytic responses, and they weren’t killing each other!

    It makes sense that IL-7 would set those CARs on the highway to directed cytolysis. After all, it’s a survival factor for T cells, especially CD8s, and also augments T cell cytolytic prowess. It was still a risk, though, to bring IL-7 into the picture, especially while treating a malignancy of T cell origin: IL-7 has been known to promote tumorigenesis.But that’s a story for another time. If you are interested in knowing how T cells kill, that story is told in this episode of our podcast where Jatin and Ash detail all that goes into cytolysis.

    Header made using Canva


    Want your article featured in Antibuddies blog? Contact editor-in-chief Kevin Merchant at antibuddies1@gmail.com.

  • Macrophages prevent your renal system from clogging

    Macrophages prevent your renal system from clogging

    If you haven’t heard about kidney stones, have you been living under a rock? It is a very well-known disease that affects approximately 11% of men and 6% of women in the United States. Its medical term is nephrolithiasis and it accounts for small particles that agglutinate into bigger ones in the distal nephron (remember, a nephron is a functional unit of the kidney) and we call them nephrolites. The most common type of nephrolites are made of calcium oxalate. 

    In this study, He and colleagues were interested in the development of these nephrolites. They postulated that because kidneys are populated with macrophages, they could be responsible for clearing out the urine contents. Is this true and if it is, how is it done?

    Okay, I will not keep you in the dark – yes it is true!

    According to this study, macrophages could sample the urine content and help in clearing out particles. Macrophages in the kidney medulla extended their protrusions into the medulla, and the same was not observed in the cortex. By electron microscopy it was confirmed that instead of squeezing between the cells, macrophages opted for a “transcellular” route, meaning, they extended their protrusions through epithelial cells. During nephrolithiasis, integrin numbers in macrophages and osteopontin numbers in epithelial cells were increased. Blocking their connection accelerated the formation of nephrolites, suggesting the mechanism for transcellular protrusion. The researchers confirmed that these protrusions had higher lysosomal activity, pointing towards phagocytosis. 

    To confirm this, they created two experimental set-ups where they intravenously injected mice with fluorescently labelled sinistrin (commonly used to test glomerular filtration ratio GFR, or kidney functionality) or fluorescently labelled beads (1 micron in size). During both of the set-ups, after 1-2 hours of administering the injection, medullar macrophages contained fluorescently labelled particles. When the macrophages were absent, bead retention was observed, suggesting that urine flushing on its own is not enough to remove the big particles. These same macrophages with the beads were later observed in the urine, leading to an “escorting” strategy of macrophages consuming particles and bringing them outside the body. 

    Next, they depleted macrophages from mice and induced an acute hyperoxaluria model (a lot of oxalate crystals). Mice without any macrophages had increased nephrolithiasis with elevated pro-inflammatory cytokines and neutrophils (if you are already asking this question: no, depleting neutrophils did not change the bead retention). Contrary to this, if the macrophages were present, 24h post the oxalate injection while the crystals were forming, they surrounded the crystals, leading to possible phagocytosis accompanied by no inflammation. This was followed by elevated macrophage number in urine. 

    As we know, kidney stones usually happen during the later ages. In agreement with that, aged mice with absent macrophages had higher levels of deposits spotted in the medulla, compared to counterparts with macrophages. However, the absence of macrophages did not affect urine filtration.

    Since this study was performed in mice, I do admit, that I would love to see how it translates to human candidates. Nonetheless, it opens new doors for possible kidney stone therapy. As we all know, for now, the best therapy is “to drink a lot of fluid and pee it out”. It is usually pain-free, but in some patients that is not the case, as kidney stone formation is followed with a lot of pain which sometimes causes a need for laser-induced breaking of big stone particles and, yes, “pee it out”. These kidney stones can also sometimes “get lost” which could again result in a lot of pain for patients. Understanding the underlying issue: whether in patients with nephrolithiasis there is no integrin-osteopontin connection or no medullar macrophages, could open new doors for treatment and lead patients “to relieve themselves”.

    If you want know more about renal immunology check out our podcast on sterile inflammation: https://antibuddies.org/2024/01/29/monolog-14-sterile-inflammation/


    Want your article featured in Antibuddies blog? Contact editor-in-chief Kevin Merchant at antibuddies1@gmail.com.